The objectives of our current research (increasing the sample size to 310 severe septic patients, and determining serum SP levels at days 1, 4, and 8 of severe sepsis diagnosis) were to determine whether there is an association between serum SP levels during the first week and sepsis mortality, sepsis severity, serum levels of TNF-α and IL-10 (as pro-inflammatory and anti-inflammatory cytokine, respectively), and whether serum SP levels during the first week could be used as a biomarker of sepsis mortality. This evidence concerns the gene TNF and Sepsis.